GSK PLC (GSK) reports a robust 17% increase in specialty medicines sales, while vaccine sales face a 6% decline, impacting ...

GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the ...

In its update, GSK reported a 17% rise in specialty medicines across its HIV, cancer, and respiratory business to £2.93 ...

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an ...

GSK announced on Thursday that its monoclonal antibody ‘Nucala’, or mepolizumab, delivered a statistically significant and ...

GSK's Q1 2025 earnings will reveal progress in specialty medicines amid regulatory headwinds. Learn what to watch when the ...

Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ETCompany ParticipantsConstantin Fest - Head of IREmma Walmsley - CEOLuke Miels ...

UK pharma major GSK (LSE: GSK) has published results from its Phase III MATINEE trial evaluating Nucala (mepolizumab) in ...

GSK plc GSK reported first-quarter 2025 core earnings of $1.13 per American depositary share (ADS), which beat the Zacks ...

Data from the NERO study was presented at the American Association of Cancer Research (AACR) Annual Meeting 2025.

With mepolizumab vs. placebo, patients with COPD and type 2 inflammation experienced significantly fewer moderate/severe ...

Q1 2025 Earnings Call Transcript April 30, 2025 GSK plc beats earnings expectations. Reported EPS is $1.13, expectations were ...